<DOC>
	<DOCNO>NCT01608412</DOCNO>
	<brief_summary>The study hypotheses test study : - Conversion everolimus 3 month post-transplantation safe effective ; - Accurate noninvasive molecular diagnostic test replace biopsy 3 month pre-conversion ( diagnosis subclinical cellular and/or humoral rejection , tissue fibrosis calcineurin inhibitor-induced nephrotoxicity ) kidney transplant recipient ; - Follow-up biopsy 12 month post-conversion ( diagnosis tissue fibrosis ) replace accurate noninvasive molecular diagnostic test kidney transplant recipient .</brief_summary>
	<brief_title>A Clinical Trial Assess Efficacy Safety Conversion Everolimus</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients undergo first living deceaseddonor kidney transplant maintain function graft 3 month posttransplant ; Older 18 year ; Panelreactive antibody lower 20 % ; Baseline immunosuppression tacrolimus , mycophenolate sodium ( MPS ) prednisone randomization 3 month . eGFR &lt; 35 mL/min randomization ; Urine proteintocreatinine ratio &gt; 0.8 randomization ; Episode acute rejection Banff histological classification &gt; 1A first 3 month posttransplant ; Cholesterol &gt; 350 mg/dL triglyceride &gt; 400 mg/dL therapy randomization ; Active infection randomization ; Chronic liver disease ; Refusal participate study ; Contraindications kidney biopsy ; Biopsy find 3 month posttransplant include borderline rejection , cellular rejection antibodymediated rejection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>renal transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>molecular evaluation</keyword>
</DOC>